About Academician Chen Lin
Academician Chen Lin (陈凛) is Chief Physician, Professor, Doctoral Supervisor, Academician of the Chinese Academy of Engineering, and one of China's foremost authorities on gastric cancer surgery, gastrointestinal oncology, and minimally invasive gastrointestinal surgery, based at Changhai Hospital, Naval Medical University (Second Military Medical University) — one of China's premier military-affiliated academic medical centers and a nationally recognized center of excellence in gastrointestinal surgery, oncology, and digestive endoscopy. Academician Chen is widely recognized as one of the defining figures of modern gastric cancer surgery in China, having made foundational contributions to the standardization of radical gastrectomy, the development of laparoscopic and robotic gastric cancer surgery, and the establishment of evidence-based treatment protocols for gastric cancer that have directly improved survival outcomes for hundreds of thousands of patients across China.
Gastric cancer remains one of the most prevalent and lethal malignancies in China and East Asia, accounting for a disproportionate share of the global gastric cancer burden. The surgical management of gastric cancer — particularly the performance of D2 radical gastrectomy with adequate lymph node dissection, the integration of perioperative chemotherapy, and the application of minimally invasive techniques that reduce surgical morbidity without compromising oncological outcomes — requires a surgeon with deep expertise in gastric cancer biology, surgical anatomy, and the technical demands of complex upper gastrointestinal surgery. Academician Chen's career has been defined by his commitment to raising the standard of gastric cancer surgery across China, through both his own clinical practice and his role in training surgeons, developing guidelines, and conducting the clinical trials that have established the evidence base for current treatment standards.
Academician Chen's clinical expertise extends beyond gastric cancer to encompass the full spectrum of gastrointestinal oncology and surgery, including colorectal cancer, gastrointestinal stromal tumors (GIST), esophageal cancer, and benign gastrointestinal conditions requiring surgical intervention. He has particular expertise in laparoscopic and robotic gastrointestinal surgery, having been a pioneer of minimally invasive approaches for gastric and colorectal cancer in China, and in the multidisciplinary management of locally advanced and metastatic gastrointestinal cancers integrating surgery, chemotherapy, targeted therapy, and immunotherapy.
Hospital Affiliation: Changhai Hospital, Naval Medical University
Changhai Hospital (长海医院), affiliated with Naval Medical University (formerly Second Military Medical University), is one of Shanghai's largest and most respected tertiary care hospitals and a national leader in gastroenterology, gastrointestinal surgery, digestive endoscopy, and oncology. The Department of General Surgery at Changhai Hospital is a national key clinical specialty, and its gastric cancer and gastrointestinal surgery program is one of the most active and experienced in China, performing a high volume of radical gastrectomy and colorectal cancer resections annually. The department is a national training center for laparoscopic and robotic gastrointestinal surgery and has been the site of landmark clinical trials in gastric cancer treatment.
The hospital's gastrointestinal oncology program is supported by a multidisciplinary tumor board, advanced laparoscopic and robotic surgical platforms (including the da Vinci surgical system), intraoperative fluorescence imaging for sentinel lymph node mapping, a dedicated gastric cancer research laboratory, and a full range of systemic oncology treatments through Changhai Hospital's oncology department. The department maintains active research collaborations with gastric cancer centers in Japan, South Korea, Germany, and the United States, and has been the site of numerous national and international clinical trials evaluating perioperative chemotherapy, targeted therapy, and immunotherapy in gastric cancer.
Clinical Expertise
- Gastric cancer surgery — D2 radical gastrectomy (total, subtotal, and proximal); laparoscopic D2 gastrectomy; robotic-assisted gastrectomy; function-preserving gastrectomy for early gastric cancer; pylorus-preserving gastrectomy; sentinel lymph node navigation surgery; management of locally advanced gastric cancer with perioperative chemotherapy (FLOT, SOX, XELOX); conversion surgery for initially unresectable gastric cancer; palliative gastrectomy and bypass; management of gastric cancer with peritoneal metastasis including hyperthermic intraperitoneal chemotherapy (HIPEC)
- Colorectal cancer surgery — laparoscopic and robotic right and left hemicolectomy; laparoscopic and robotic anterior resection and abdominoperineal resection for rectal cancer; total mesorectal excision (TME); transanal total mesorectal excision (TaTME); management of locally advanced rectal cancer with neoadjuvant chemoradiation; lateral lymph node dissection for rectal cancer; management of colorectal cancer with liver metastases in coordination with hepatobiliary surgery
- Gastrointestinal stromal tumors (GIST) — surgical resection of primary GIST; management of GIST with imatinib and sunitinib; resection of imatinib-responsive metastatic GIST; management of imatinib-resistant GIST; coordination with medical oncology for targeted therapy sequencing
- Esophageal and gastroesophageal junction cancer — minimally invasive esophagectomy (MIE); Ivor Lewis and McKeown esophagectomy; management of gastroesophageal junction (Siewert type I-III) adenocarcinoma; perioperative chemotherapy coordination
- Multidisciplinary gastrointestinal oncology — tumor board review for complex gastric and colorectal cancer cases; integration of surgery with chemotherapy, targeted therapy (trastuzumab, ramucirumab, anti-HER2 agents), and immunotherapy (PD-1/PD-L1 inhibitors); management of hereditary colorectal cancer syndromes (Lynch syndrome, FAP)
- Benign gastrointestinal surgery — laparoscopic cholecystectomy; laparoscopic appendectomy; management of complicated peptic ulcer disease; bariatric surgery coordination; management of inflammatory bowel disease requiring surgical intervention
- Expert second opinion — review of imaging, endoscopy, pathology, and treatment records for patients with gastric or colorectal cancer who are seeking a second surgical opinion or evaluation for minimally invasive or conversion surgery; written English-language second opinion reports available through CMCS
Academic Leadership & Research Contributions
Academician Chen Lin is one of China's most prolific and internationally impactful researchers in gastrointestinal oncology and surgery. He has authored and co-authored more than 300 peer-reviewed publications in Chinese and international journals, including contributions to Journal of Clinical Oncology, Annals of Surgery, JAMA Surgery, Gastric Cancer, British Journal of Surgery, and Chinese Medical Journal. His research has focused on the standardization of D2 gastrectomy and its impact on survival outcomes in Chinese patients, the comparative outcomes of laparoscopic versus open gastrectomy for gastric cancer, the role of perioperative chemotherapy in locally advanced gastric cancer, the application of robotic surgery in gastrointestinal oncology, and the development of novel biomarkers for gastric cancer prognosis and treatment response prediction.
Academician Chen has served as editor-in-chief and editorial board member of multiple Chinese and international gastrointestinal surgery and oncology journals, and has been a principal investigator on major national research grants from the National Natural Science Foundation of China (NSFC), the National Key Research and Development Program, and the military medical research system. He is a past president of the Chinese Anti-Cancer Association Gastric Cancer Committee and has served on the scientific advisory boards of the International Gastric Cancer Association (IGCA) and the Japanese Gastric Cancer Association (JGCA). He has been a keynote speaker at IGCA, ASCO, ESMO, and the Chinese Society of Surgery annual congress, and is recognized globally as one of the most influential voices in gastric cancer surgery.
Academician Chen has trained more than 100 gastrointestinal surgery fellows and residents who now lead programs across China, and has been a principal investigator or steering committee member on multiple landmark randomized controlled trials that have shaped Chinese and international gastric cancer treatment guidelines. His election to the Chinese Academy of Engineering reflects the transformative impact of his research and clinical leadership on the management of gastric cancer in China.
Why International Patients Choose Academician Chen Lin
For international patients with a diagnosis of gastric cancer — particularly locally advanced gastric cancer, gastric cancer with peritoneal involvement, or gastric cancer requiring conversion surgery after systemic treatment — Academician Chen's combination of unmatched case volume, foundational expertise in D2 gastrectomy, and pioneering experience in laparoscopic and robotic gastric cancer surgery represents a genuinely exceptional resource. Gastric cancer is significantly more prevalent in East Asian populations, and Chinese and Japanese surgeons have accumulated the world's largest clinical experience with radical gastrectomy and the most refined surgical techniques for lymph node dissection and reconstruction.
Many international patients arrive at CMCS after receiving a diagnosis of gastric cancer at a hospital in their home country where the surgical team has limited experience with D2 gastrectomy or minimally invasive gastric cancer surgery, or where the tumor has been deemed unresectable without a thorough evaluation of conversion surgery options. Academician Chen's ability to review imaging, endoscopy, and pathology, assess resectability and the feasibility of minimally invasive approaches, evaluate the role of perioperative chemotherapy, and provide a clear, evidence-based treatment recommendation is of decisive value to patients navigating one of the most serious cancer diagnoses.
Treatment costs for gastric cancer surgery at Changhai Hospital are substantially lower than equivalent procedures in Western healthcare systems — typically 20–40% of the cost of comparable surgery in the United States, United Kingdom, or Australia — and the speed of access to specialist consultation, multidisciplinary tumor board review, and surgical planning is typically far faster than in public healthcare systems abroad. CMCS has coordinated gastric cancer consultations and surgical cases for patients from North America, Europe, Southeast Asia, and the Middle East through Academician Chen's team at Changhai Hospital.
What to Expect at Your Consultation
Consultations with Academician Chen begin with a comprehensive review of all prior imaging — including CT of the chest, abdomen, and pelvis with contrast, endoscopy and endoscopic ultrasound (EUS) reports, PET-CT if available, and pathology reports including HER2, PD-L1, MMR/MSI, and EBER status — as well as the patient's oncological history, prior treatment records, performance status, and nutritional assessment. CMCS will arrange certified translation of all medical records, imaging reports, endoscopy reports, and pathology results in advance of the consultation.
Academician Chen will assess the tumor stage and resectability, evaluate the feasibility of minimally invasive approaches, outline the recommended treatment strategy — including the role and sequencing of perioperative chemotherapy, targeted therapy, and immunotherapy — with detailed rationale, and provide a realistic assessment of expected surgical and oncological outcomes. A multidisciplinary tumor board review involving medical oncology, radiation oncology, and gastroenterology will be coordinated as appropriate. A written English-language consultation summary — including imaging interpretation, staging, recommended treatment plan, and follow-up protocol — is provided after every appointment, and CMCS will facilitate direct communication between Academician Chen's team and the patient's home oncologist and surgeon for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking gastric cancer or gastrointestinal surgery consultation with Academician Chen Lin at Changhai Hospital. Our services include priority consultation scheduling with Academician Chen's team and the multidisciplinary tumor board, certified medical record and imaging translation, pre-consultation oncological and imaging review by our clinical coordinators, surgical logistics and hospital admission coordination, visa and travel support, accommodation recommendations near Changhai Hospital, on-site interpretation throughout the consultation and surgical process, pharmacy and chemotherapy coordination, and ongoing follow-up coordination between Academician Chen's team and the patient's home physicians after return.
0 commenti